Novo Nordisk reported strong Q3 2025 results with a 15% increase in sales and 10% rise in operating profit, while narrowing its sales and operating profit guidance due to projected slower growth in its GLP-1 treatments.

• Sales growth was driven by both U.S. (15%) and international operations (16%), bolstered by one-off adjustments in the U.S. of DKK 6 billion.
• Obesity care surged 41%, led by a 24% growth in U.S. sales and an impressive 83% growth internationally.
• The company is executing a strategic transformation involving a reduction of approximately 9,000 global positions, expected to yield annual savings of DKK 8 billion by 2026.
• Rybelsus received regulatory approval in the U.S. and EU, enhancing Novo's offerings in diabetes care.
• Ongoing focus on diabetes and obesity, coupled with portfolio refinement, reaffirms Novo Nordisk's commitment to addressing major unmet medical needs.